It’s been a few years since we last spoke. Can you give our readers a refresher on the company and its history? Dr. Bedu-Addo: So, PDS Biotechnology is developing immunotherapies that train the immune ...

How did the last year play out for your coverage, and what do you see going forward? Are you optimistic? Dr. Nierengarten: Yes, I am optimistic. The reasons are based on what we saw happening last ...

So it’s been a few years since we last spoke. Let’s start with a brief overview and history of the company. Mr. Itescu: Sure. So Mesoblast has been publicly listed both on Nasdaq and the Australian ...

Tell us about the current trends and themes that are most impacting the space, the subsectors, you watch? Dr. Phipps: Sure. My coverage spans a range of biopharma companies, including large-caps such ...

Recently you wrote a wonderful article that was published in Forbes magazine. In the context of an introduction to your coverage, what inspired you to write that piece, and what are some of the main ...

Let’s start with a brief overview of the company — how it started and some milestones. Mr. Fried: The company was started back in the Bronze Age, 25 years ago. It was started by its current founder ...

We’ve spoken several times before, but can you just give our readers a brief refresher on the company and how it has evolved over the years? Mr. Do: BioVie is a biotech company that started developing ...

To start things off, I understand Vaxart is researching oral vaccines for COVID-19, norovirus, and influenza. Could you give us an overview of each program and where they are in the development ...

Interview with Ryan Zimmerman, Managing Director and Medical Technology Analyst, BTIG and former Director of Surgery at ...

Tell us briefly about Picard Medical and the history of SynCardia Total Artificial Heart. Mr. Schnegelsberg: Let me start with SynCardia and then go to Picard. SynCardia is a company with a long ...

In the context of an introduction to your coverage, could you define the life sciences space, and discuss how it differs from the biotech or medtech space? Ms. Utterback: The life science companies ...

For readers who may just be hearing about HeartBeam, explain to us what clinical problem you are trying to solve and why hasn’t that been able to be solved with existing cardiac monitoring tools? Mr.